spacer
home > ebr > winter 2003 > technical and commercial due diligence in biotech transactions: doing the right things and doing them right
PUBLICATIONS
European Biopharmaceutical Review

Technical and Commercial Due Diligence in Biotech Transactions: Doing the Right Things and Doing them Right

This article argues that conducting due diligence properly to ensure that potential risks and opportunities in biotechnology transactions are fully understood is more important than ever as M&A and technology licensing activities accelerate. There are many ways to go about conducting due diligence, and the factors that determine the right way to proceed are discussed, with the pros and cons set out for taking an in-house approach, versus hiring external consultants. Whatever approach is taken, a due diligence plan is vital, given the often short timescales in which deals need to be closed. Keys to success are ensuring that an independent view is taken and that the right questions are asked, such that the answers truly help to support the investment decision. Due diligence can be an intensive and time-consuming process so the task should not be underestimated or left to the last minute - while it has costs in terms of time or professional fees, cutting corners can turn out to be far more costly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Simon Shohet, Head of Healthcare and Life Sciences Consulting Team at Cambridge Consultants Ltd

Simon Shohet has been a strategic and commercial advisor and analyst for organisations in the biotechnology and health care industry for over 12 years. Presently, he leads the Healthcare and Life Sciences Consulting team at Cambridge Consultants Ltd (CCL), a sister company of the international management consulting firm Arthur D Little. His team works for European, US and Asia-Pacific-based corporations as well as start-ups and government agencies, helping them to gain competitive advantage through strategic exploitation of life science and biomedical technologies. Before entering consulting he held posts at the Confederation of British Industry (CBI) as a Biotechnology Policy Adviser and London Business School as a Research Fellow in technology economics. He holds a PhD in Microbiology from University College London, and a BSc from the University of Edinburgh. Simon has published numerous papers and articles in management and scientific literature.

spacer
Simon Shohet
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the 11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers
 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement